Oron Catts and Ionat Zurr talk about the future with Bioart. [ + ]

An international conference to be held in Australia next week has particular relevance for the future of Australia's biotech and pharmaceutical industries, writes Iain Scott. [ + ]

Chris Goodnow talks about defining the mammalian phenome and how this may pan out in the future. [ + ]

Melissa Trudinger looks at the issues that are set to arise as debate begins again on stem cell research in Australia. [ + ]

Max Bennett spoke with Susan Williamson about what's in store for neuroscience in coming years. [ + ]

Susan Williamson spoke with eminent scientist Len Harrison about his views for the future of diabetes research. [ + ]

Nigel Poole offers 10 glimpses of what Australian life science commercialisation could look like in 2015. [ + ]

Collaboration and cooperation are key when taking research to market, writes Rowan Gilmore. [ + ]

A new environment for pharmaceutical companies is on the horizon and it will be the fittest who survive, predicts Ian Nisbet. [ + ]

The life sciences can learn from the IT revolution, Prashant Tyagi explains. [ + ]

With technology advancing so rapidly in many potential commercial areas of life science, patent attorneys, intellectual property (IP) and commercial lawyers, and lawmakers will face a number of challenges over the next 10 years, says Trevor Davies. [ + ]

Advocates and opponents of stem cell research across Australia are gearing up for the reignition of the debate that polarised Australia's state and federal governments in 2002. [ + ]

A change is needed in the way science is taught, argues Kathy Takayama. [ + ]

Over the next decade two powerful forces, economics and technology, will reshape teaching hospital laboratories, writes Ross Vining. [ + ]

Australians lead the way in vaccine research for malaria and other infectious diseases, writes Michael Good. [ + ]